Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (98)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (136)
  2. Hematologic Malignancies, Division of (136)
  3. Center for Hematologic Malignancies (88)
  4. Hematology-Oncology Fellows (81)
  5. Lymphoma (78)
  6. Weinberg Fellows (58)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (10)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. British Journal of Haematology (5)
  6. Clinical Lymphoma, Myeloma and Leukemia (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. John Wiley & Sons (6)
  6. Taylor & Francis Group (5)

More Publishers

Results (136)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study
    Meeting Abstract

    Dickinson, M. J.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Cartron, G.; Corradini, P.; Bartlett, N. L.; Iacoboni, G.; Khan, C.; Hertzberg, M. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CDI9-CD28 (RO7443904) combination with glofitamab enhances T-cell proliferation and effector function in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Meeting Abstract

    Korfi, K.; Wilson, S.; Jiang, Z.; Christiansen, A.; Krishnan, S.; Jamois, C.; Blank, A.; Epp, A.; Silva, A.; Knuckles, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration epcoritamab + R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features: Long-term results from the EPCORE NHL-2 trial
    Meeting Abstract

    Falchi, L.; Offner, F.; de Vos, S.; Brody, J.; Cordoba, R.; Linton, K.; Snauwaert, S.; Clausen, M. R.; Oki, T.; Steele, A. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
    Blood (2024)

    Fulltext@MSK | Save